XPC Polymorphism and Risk for Lung Cancer in North Indian Patients Treated with Platinum Based Chemotherapy and Its Association with Clinical Outcomes

  • Shweta Lawania
  • Navneet Singh
  • Digamber Behera
  • Siddharth Sharma
Original Article

Abstract

Xeroderma pigmentosum complementation group C plays an important role in the human repair system. As reported in previous studies its polymorphism are associated with lung cancer susceptibility. The purpose of this study is to investigate the association of XPC gene with lung cancer susceptibility, overall response and clinical outcomes amongst North Indians. A hospital based study of 370 lung cancer cases and 370 healthy controls was conducted and genotypes were determined using PCR-RFLP assay. Results were assessed using logistic linear regression adjusted for age, sex and smoking status. Survival analysis was conducted using Kaplan-Meier survival analysis and Cox regression analysis. The treatment outcomes of 167 lung cancer patients treated with platinum based chemotherapy were evaluated.The mutant genotypic variant of XPC Lys939Gln has been associated with elevated risk of lung cancer(OR:2.30;95%CI:1.41-3.73;p=0.0007) whereas XPC Ala499Val showed a highly protective effect (OR:0.25;95%CI:0.10-0.63;p=0.003). The mutant genotype of XPC Lys939Gln presented a higher risk of developing lung cancer in heavy smokers (OR: 3.71; 95%CI:1.46-9.45; p=0.005). The survival analysis presented that heterozygous genotype showed least survival in comparison with mutant genotype in XPC Ala499Val genetic variant whereas no significant association was observed in XPC Lys939Gln. In conclusion, XPC Lys939Gln is associated with significant risk towards the lung cancer whereas on contrary XPC Ala499Val shows a protective effect.

Keywords

Lung cancer Xeroderma pigmentosum group C;PCR-RFLP;overall survival Platinum based chemotherapy 

Abbreviations

ADCC

(Adenocarcinoma)

HR

(Hazard ratio)

MST

(Mean survival time)

ns SNPs

(Non synonymous single nucleotide polymorphism)

OR

(Odds ratio)

SCLC

(Small cell lung cancer)

SQCC

(Squamous cell carcinoma)

XPC

(Xeroderma pigmentosum group C)

References

  1. 1.
    Lyon (2003) IARC: tobacco smoke and involuntary smoking. IARCGoogle Scholar
  2. 2.
    Malik PS, Raina V (2015) Lung cancer: prevalent trends & emerging concepts. Indian JMed Res 141(1):5–7CrossRefGoogle Scholar
  3. 3.
    Corrao MA, Guindon GE, Cokkinides V, Sharma N (2000) Building the evidence base for global tobacco control. Bull World Health Organ 78:884–890PubMedPubMedCentralGoogle Scholar
  4. 4.
    Parkin DM, Pisani P, Lopez AD, Masuyer E (1994) At least one in seven cases of cancer is caused by smoking: global estimates for 1985. Int J Cancer 59:494–504CrossRefPubMedGoogle Scholar
  5. 5.
    Shields PG, Harris CC (2000) Cancer risk and low-penetrance susceptibility genes in gene–environment interactions. J Clin Oncol 18:2309–2315CrossRefPubMedGoogle Scholar
  6. 6.
    Lindahl T, Wood RD (1999) Quality control by DNA repair. Science 286:1897–1905CrossRefPubMedGoogle Scholar
  7. 7.
    Sancar A (1995) DNA repair in humans. Annu Rev Genet 29:69–105CrossRefPubMedGoogle Scholar
  8. 8.
    de Laat WL, Jaspers NGJ, Hoeijmakers JHJ (1993) Molecular mechanism of nucleotide excision repair. Genes Dev 13:768–785CrossRefGoogle Scholar
  9. 9.
    Wei Q, Spitz MR (1997) The role of DNA repair capacity in susceptibility to lung cancer: a review. Cancer Metastasis Rev 16:295–307CrossRefPubMedGoogle Scholar
  10. 10.
    Matutani C, Araki M, Sugawasa K, van der Spek PJ, Yamada A, Uchida A, Maekawa T, Bootsma D, Hoeijmakers JHJ, Hanaoka F (1997) Identification and characterizationof XPC binding domain ofh HR23B. Mol Cell Biol 17:6915–6923CrossRefGoogle Scholar
  11. 11.
    Khan SG, Metter EJ, Tarone RE, Bohr VA, Grossman L, Hedayati M, Bale SJ, Emmert S, Kraemer KH (2000) A new xeroderma pigmentosum group C poly (AT) insertion/deletion polymorphism. Carcinogenesis 21:1821–1825CrossRefPubMedGoogle Scholar
  12. 12.
    Sanyal S, Festa F, Sakano S, Zhang Z, Steineck G, Norming U, Wijkstrom H, Larsson P, Kumar R, Hemminki K (2004) Polymorphisms in DNA repair and metabolic genes in bladder cancer. Carcinogenesis 25:729–734CrossRefPubMedGoogle Scholar
  13. 13.
    Forsti A, Angelini S, Festa F, Sanyal S, Zhang Z, Grzybowska E, Pamula J, Pekala W, Zientek H, Hemminki K, Kumar R (2004) Single nucleotidepolymorphisms in breast cancer. Oncol Rep 11:917–922PubMedGoogle Scholar
  14. 14.
    Sodhi KK, Bahl C, Singh N, Behera D, Sharma S (2015) Functional genetic variants in pre-miR-146a and 196a2 genes are associated with risk of lung cancer in North Indians. Future Oncol 11(15):2159–2173CrossRefPubMedGoogle Scholar
  15. 15.
    Sugasawa K, Ng JM, Masutani C, Iwai S, van der Spek PJ et al (1998) Xeroderma pigmentosum group C protein complex is the initiator of global genome nucleotide excision repair. Mol Cell 2:223–232CrossRefPubMedGoogle Scholar
  16. 16.
    Raaschou-Nielsen O, Sorensen M, Overvad K, Tjonneland A, Vogel U (2008) Polymorphisms in nucleotide excision repair genes, smoking and intake of fruit and vegetables in relation to lung cancer. Lung Cancer 59:171–179CrossRefPubMedGoogle Scholar
  17. 17.
    Bak H, Autrup H, Thomsen BL, Tjonneland A, Overvad K et al (2008) Bulky DNA adducts as risk indicator of lung cancer in a Danish case-cohort study. Int J Cancer 1189:1618–1622Google Scholar
  18. 18.
    Jin B, Dong Y, Zhang X, Wang H, Han B (2014) Association of XPC polymorphisms and lung cancer risk. A meta-analysis. Plos one 9(4):e93937CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Kusumoto R, Masutani C, Sugasawa K et al (2007) Diversity of the damage recognition step in the global genomic nucleotide excision repair in vitro. Mutat Res 485:219–227CrossRefGoogle Scholar
  20. 20.
    Yokoi M, Masutani C, Maekawa T, Sugasawa K, Ohkuma Y, Hanaoka F (2000) The xeroderma pigmentosum group C protein complex XPC-HR23B plays an important role in the recruitment of transcription factor IIH to damaged DNA. J Biol Chem 275:9870–9875CrossRefPubMedGoogle Scholar
  21. 21.
    Sugasawa K, Shimizu Y, Iwai S, Hanaoka F (2002) A molecular mechanism for DNA damage recognition by the xeroderma pigmentosum group C protein complex. DNA Repair 1:95–107CrossRefPubMedGoogle Scholar
  22. 22.
    Shen M, Berndt SI, Rothman N, Demarini DM, Mumford JL et al (2005) Polymorphisms in the DNA nucleotide excision repair genes and lung cancer risk in Xuan Wei, China. Int J Cancer 116:768–773CrossRefPubMedGoogle Scholar
  23. 23.
    Vodicka P, Kumar R, Stetina R, Sanyal S, Soucek P, Haufroid V, Dusinska M, Kuricova M, Zamecnikova M, Musak L, Buchancova J, Norppa H et al (2004) Genetic polymorphisms in DNA repair genes and possible links with DNA repair rates, chromosomal aberrations and single-strand breaks in DNA. Carcinogenesis 25:757–763CrossRefPubMedGoogle Scholar
  24. 24.
    Deutsch-Wenzel RP, Brune H, Grimmer G, Dettbarn G, Misfeld J (1983) Experimental studies in rat lungs on the carcinogenicity and dose-response relationships of eight frequently occurringenvironmental polycyclic aromatic hydrocarbons. J Natl Cancer Inst 71:539–544PubMedGoogle Scholar
  25. 25.
    Hoffman (1993) Cigarette smoking and adenocarcinoma of the lung: the relevance of nicotine-derived nitrosamines. J Smoking Relat Disord 4:165–190Google Scholar
  26. 26.
    Xing D, Tan W, Wei Q, Lin D (2002) Polymorphisms of the DNA repair gene XPD and risk of lung cancer in a Chinese population. Lung Cancer 38:123–129CrossRefPubMedGoogle Scholar
  27. 27.
    Yin J, Vogel U, Ma Y, Guo L, Wang H, Qi R (2006) Polymorphism of the DNA repair gene ERCC2 Lys751Gln and risk of lung cancer in a northeastern Chinese population. Cancer Genet Cytogenet 169:27–32CrossRefPubMedGoogle Scholar
  28. 28.
    Zhu Y, Lai M, Yang H, Lin J, Huang M, Grossman HB, Colin PD, Wu X (2006) Genotypes, haplotypes and diplotypes of XPC and risk of bladder cancer. Carcinogenesis 28(3):698–703CrossRefPubMedGoogle Scholar
  29. 29.
    Letkova L, Matakova T, Musak L, Sarlinova M, Krutakova M, Slovakova P, Kavcova E, Jakusova V, Janickova M, Drgova A, Berzinec P, Halasova E (2013) DNA repair genes polymorphism and lung cancer risk with the emphasis to sex differences. Mol Biol Rep 40:5261–5273CrossRefPubMedGoogle Scholar
  30. 30.
    Qiao Y, Spitz MR, Guo Z, Mohammad H, Lawrence G, Kenneth KH, Wei Q (2002) Rapid assessment of repair of ultraviolet DNA damage with a modified host-cell reactivation assay using a luciferase reporter gene and correlation with polymorphisms of DNA repair genes in normal human lymphocytes. Mutat Res 509:165–174CrossRefPubMedGoogle Scholar
  31. 31.
    Nelson HH, Kelsey KT, Mott LA, Karagas MR (2002) The XRCC1 Arg399Gln polymorphism, sunburn, and non-melanoma skin cancer: evidence of gene-environment interaction. Cancer Res 62:152–155PubMedGoogle Scholar
  32. 32.
    Bowen AR, Hanks AN, Allen SM, Alexander A, Diedrich MJ, Grossman D (2003) Apoptosis regulators and responses in human melanocytic and keratinocytic cells. J Invest Dermatol 120:48–55CrossRefPubMedGoogle Scholar
  33. 33.
    Hu Z, Wang Y, Wang X, Liang G, Miao X, Xu Y, Tan W, Wei Q, Lin D, Shen H (2005) DNA repair gene XPC genotypes/haplotypes and risk of lung cancer in a Chinese population. Int J Cancer 115:478–483CrossRefPubMedGoogle Scholar
  34. 34.
    Matakideu A, Eisen T, Bridle H, Houlsten S. R. (2006) Nucleotide excision repair polymorphism modulate overall lung cancer survival and responsiveness to platinum based chemotherapy agents. Jr of Clinical Oncology 24: 10004.Google Scholar
  35. 35.
    Vicent G, Mar T (2008) Influence of DNA damage and repair upon the risk of treatment related leukemia. Leuk Lymphoma 49:204–217CrossRefGoogle Scholar
  36. 36.
    Gao R, Price DK, Sissung T, Reed E, Figg WD (2008) Ethnic disparities in Americans of European descent versus Americans of African descent related to polymorphic ERCC1, ERCC2, XRCC1, and PARP1. Mol Cancer Ther 7:1246–1250CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Shi C, Qian J, Ma M, Zhang Y, Han B (2014) Notch 3 protein, not its gene polymorphism, is associated with the chemotherapy response and prognosis of advanced NSCLC patient. Cell Physiol Biochem 34:743–752CrossRefPubMedGoogle Scholar
  38. 38.
    Wu F, Zhang J, Liu Y, Zheng Y, Hu N (2013)HIF1alpha genetic variants and protein expressions determine the response to platinum based chemotherapy and clinical outcome in patients with advanced NSCLC. Cell Physiol Biochem 32: 1566-1576.Google Scholar
  39. 39.
    Sullivan I, Salazar J, Majem M, Pallares C, Del Rio E, Paez D, Baiget M, Barnadas (2014) A: pharmacogenetics of the DNA repair pathways in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Cancer Lett 353: 160–166.Google Scholar
  40. 40.
    Tiseo M, Bordi P, Bortesi B, Boni L, Boni C, Baldini E, Grossi F, Recchia F, Zanelli F, Fontanini G, Naldi N, Campanini N, Azzoni C, Bordi C, Ardizzoni A (2013) ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin. Br J Cancer 108:1695–1703CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Xu TP, Shen H, Liu LX, Shu YQ (2013) Association of ERCC1-C118T and -C8092A polymorphisms with lung cancer risk and survival of advanced-stage non-small cell lung cancer patients receiving platinum-based chemotherapy: a pooled analysis based on 39 reports. Gene 526:265–274CrossRefPubMedGoogle Scholar
  42. 42.
    Li XD, Han JC, Zhang YJ, Li HB, Wu XY (2013) Common variations of DNA repair genes are associated with response to platinum-based chemotherapy in NSCLCs. Asian Pac J Cancer Prev 14:145–148CrossRefPubMedGoogle Scholar

Copyright information

© Arányi Lajos Foundation 2017

Authors and Affiliations

  • Shweta Lawania
    • 1
  • Navneet Singh
    • 2
  • Digamber Behera
    • 2
  • Siddharth Sharma
    • 1
  1. 1.Department of BiotechnologyThapar UniversityPunjabIndia
  2. 2.Department of Pulmonary MedicinePost Graduate Institute of Medical Education & Research (PGIMER), Sector 14ChandigarhIndia

Personalised recommendations